Press Releases

Press Releases
Date Title and Summary View
12/05/2016 Results to be presented today in poster at 58th American Society of Hematology (ASH) Annual Meeting and Expo ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that results of its Phase 1/2 clinical trial on its lead drug candidate GMI-1271 conti...
11/10/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2016 HEALTHCARE CONFERENCEWHEN: NOVEMBER 15, 2016 AT 4:30 PM E...
11/08/2016 - Data illustrate potential for synergy between drug candidate GMI-1359 and PD-L1 antagonists when used in combination to treat solid tumors ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that data showing enhanced effectiveness of an antibody a...
11/04/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the quarter ended September 30, 2016. "For GlycoMimetics, the third quarter was highlighted by continued achievements in our clin...
11/03/2016 Oral presentation and six posters illustrate advancement of GlycoMimetics' pipeline Poster presentation will update clinical data from on-going AML study of GMI-1271 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announ...
09/14/2016 Trial to test candidate for second blood cancer type among patients responding poorly to standard therapy ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced it has dosed its first patient in a Phase 1 clinical trial of its novel E-selectin antagonis...
09/08/2016
PDF
Add to Briefcase
09/06/2016 First-in-Humans Study of Third GlycoMimetics Drug Candidate ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first healthy volunteers in a new Phase 1 clinical trial evaluating its novel combined E-selectin and CXCR4 antagonist GMI-...
08/16/2016 Research shows effectiveness in stabilizing atherosclerotic plaques, reducing risk of further injury due to reduced blood flow ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of results from a preclinical study that showed its ...
08/08/2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET. To access the live webcast...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase